SAN FRANCISCO and SUZHOU, China, May 10, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a third Breakthrough Therapy Designatio

Authorization advances Fractyl Health to a dual clinical-stage company, with Revita ® in pivotal development for post-GLP-1 weight maintenance and Rejuva ® entering first-in-human studies for type 2 diabetes First-in-human dosing and preliminary data expected in the second half of 2026, subject to site activation Rejuva ® clinical development funded within existing cash runway into early 2027, beyond anticipated REMAIN-1 Pivotal data readout; no change to capital plans BURLINGTON, Mass., May

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Lysoway Therapeutics today announced that the first participant has been successfully dosed on May 5, 2026 in the Company’s Phase I clinical trial of LW-1017, a potent, selective, and highly brain-penetrant small-molecule TRPML1 agonist being developed for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. The Phase I study is being conducted in Melbourne, Australia and is designed to evaluate the safety, tolerability, and pharm

CAMBRIDGE, Mass. , May 11, 2026 /PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced multiple presentations, including three oral presentations and a late-breaking poster presentation at the upcoming American Thoracic Society (ATS) 2026 International Conference, which will take place May 15-20, 2026, in

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively Including proceeds from underwritten public offering in April, existing cash resources expected to fund operations at least into 2028 CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics,

iStock, Alona Horkova Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to accelerate drug review. The FDA has approved the use of Partner Therapeutics’ Bizengri to treat patients with cholangiocarcinoma carrying a specific genetic mutation—a decision that came just days after the drug was awarded the regulator’s national priority voucher. Bizengri, a HER2- and HER3-directed bispecific antibody that received accelerated approva

NAARDEN, the Netherlands and MIAMI, May 11, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the

The advent of personalized medicine has ushered in a new era for healthcare and brought hope for patients facing rare diseases and previously untreatable cancers. Cell and gene therapies (CGT) represent a confluence of medical research and scientific technology decades in the making that has grown into a revolution in patient treatment. These living medicines present a logistical challenge unlike anything previously seen in the pharmaceutical industry. Unlike traditional shelf-stable drugs, CGTs

iStock, wassam siddique New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on maintaining low levels of two key lipoproteins. Big pharma is all in, looking to improve on the standard statins to help vanquish America’s number one killer: heart disease. Heart disease has remained America’s number one killer for a century. Recent guidelines, however, underscore the potential opportunity for pharmaceutical companies in treating a key c

BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. “The first quarter of 2026 marked another exciting quarter for Gain, as we continued to build on the important advancements achieved in 202